Illumina
San Diego, California, USA
Illumina is involved in genomics and drug discovery, collaborating with NVIDIA for sequencing and multiomics analysis.
How We Help
Problem Statement
Illumina solves the challenge of accurately and efficiently analyzing genetic variation and biological function to advance genomics research, clinical applications, and personalized medicine.
Core Technology
Genomics, sequencing, multiomics analysis
Key Differentiators
Market Leadership and Scale; Proprietary and Accurate Technology (Sequencing by Synthesis (SBS) technology, XLEAP-SBS chemistry); Integrated Ecosystem (sequencers, reagents, bioinformatics software like DRAGEN and BaseSpace, global service network); Cost-Efficiency for High-Volume Projects; Broad Application Range; Global Presence and Support.
Clinical Focus
Enabling applications like whole-genome sequencing, genotyping, gene expression and transcriptome profiling, and epigenetics for various clinical areas.
Target Customers
Researchers, clinicians, diagnostic laboratories, pharmaceutical companies, and institutions involved in personalized medicine, oncology, genetic diseases, infectious diseases, and reproductive health.
Product Stage
Mature
Company Info
- Business Model
- B2B, razor-and-blade model, sale of integrated systems (sequencing platforms, microarrays) and consumables, software and service subscriptions.
- Founded
- 1998
- Total Funding
- 28,000,000
- Website
- illumina.com
Categories
Technologies
MedStartr Index Score
?What do you think of Illumina?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.